153 related articles for article (PubMed ID: 29199670)
21. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
Hensing T; Chawla A; Batra R; Salgia R
Adv Exp Med Biol; 2014; 799():85-117. PubMed ID: 24292963
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for lung cancer.
Petrosyan F; Daw H; Haddad A; Spiro T
Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Ganti AK
Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
[TBL] [Abstract][Full Text] [Related]
25. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
26. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.
Cheng L; Zhang S; Alexander R; Yao Y; MacLennan GT; Pan CX; Huang J; Wang M; Montironi R; Lopez-Beltran A
Future Oncol; 2011 Apr; 7(4):519-41. PubMed ID: 21463141
[TBL] [Abstract][Full Text] [Related]
27. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
28. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
29. Lung adenocarcinoma: lessons in translation from bench to bedside.
Sangodkar J; Katz S; Melville H; Narla G
Mt Sinai J Med; 2010; 77(6):597-605. PubMed ID: 21105123
[TBL] [Abstract][Full Text] [Related]
30. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
31. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
32. Resistance to Therapy.
Rivera G; Wakelee HA
Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
[TBL] [Abstract][Full Text] [Related]
33. Pathway targets to explore in the treatment of non-small cell lung cancer.
Weiss GJ; Kingsley C
J Thorac Oncol; 2008 Nov; 3(11):1342-52. PubMed ID: 18978571
[TBL] [Abstract][Full Text] [Related]
34. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
36. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Cella D
Semin Oncol; 2003 Feb; 30(1 Suppl 1):39-48. PubMed ID: 12644983
[TBL] [Abstract][Full Text] [Related]
37. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
38. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
[TBL] [Abstract][Full Text] [Related]
39. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C; Zhou F; Shen J; Zhao J; O'Brien M
Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
[TBL] [Abstract][Full Text] [Related]
40. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Park S; Park S; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Kim YW; Heo DS
Korean J Intern Med; 2016 Nov; 31(6):1140-1149. PubMed ID: 27017943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]